It has been repeatedly demonstrated that choline metabolism is altered in a wide variety of cancers. In breast tumours, the choline metabolite profile is characterized by an elevation of phosphocholine and total choline-compounds. This pattern is increasingly being exploited as biomarker in cancer diagnosis.
Background
Choline (Cho) is a dietary component essential for the normal function of all cells [11] . The intracellular metabolism of choline in breast is partitioned among two major pathways: (a) synthesis of phosphatidylcholine (PtdCho) and (b) oxidation to produce the methyl donor betaine.
Choline metabolism and choline-derived metabolites can exhibit remarkable alterations as a result of malignant proliferation. The abnormal choline metabolite profile typical of cancers is characterized by an elevation of phosphocholine (PCho) and total choline (tCho) containing metabolites. This has been demonstrated by numerous in vivo magnetic resonance spectroscopy (MRS) studies [4] . The major molecular causes of the increased PCho and tCho levels in cancer cells and tumors include an increased expression and activity of choline kinase alpha (CHKalpha), an increased activities of phosphatidylcholine-specific phospholipase C and D (PLC and PLD), and phospholipases A2 (PLA2) [5] . Moreover MRS investigation on breast cancers recognised the occurrence of a switch from high glycerophosphocholine (GPCho) and low PCho to low GPCho and high PCho in presence of cancerogenesis.
In synthesis all of the altered metabolites participate in the biosynthetic and catabolic pathways of the major membrane phospholipid PtdCho, as shown in the schematic diagram (Fig. 1) .
In vivo detection of choline metabolites by proton magnetic resonance spectroscopy ( 1 H MRS) has been proven to be useful in the diagnosis of cancer [10] and in monitoring the response of tumors to anticancer therapy [1] . However it is not possible to resolve free choline from its phosphorylated derivatives in vivo, even at high magnetic field strengths, because of the broad linewidths that result from restricted molecular motion and magnetic field inhomogeneities. This is why the discovery of cancer biomarkers and potential drug targets necessarily involve metabolomic investigation on ex vivo samples by techniques such as high resolution NMR, mass spectrometry and high resolution magic angle spinning (HR-MAS).
The present work builds on the established correlation between choline metabolism modification and malignant tumor proliferation and focuses on three cancer indicators, namely tCho and PCho concentrations and PCho/GPCho ratio. A metabonomic study is conducted on three breast carcinoma specimens obtained by surgical excision, each one accompanied by a control tissue sample taken outside the tumor margin. The study entails tissue extraction of metabolites and a parallel analysis conducted by onedimensional (1D) 1 H NMR spectroscopy, taken as standard technique, and an optimized implementation of a LC/ESI-MS method.
The key feature of the method, which was already reported in 2011 [7] , is the adoption of a polar stationary phase HILIC (the acronym stands for Hydrophilic Interaction LIquid Cromatography) that can retain polar compounds on the column without the disadvantages of using solvents that are immiscible with water, as used in traditional normal phase HPLC. The high amount polar organic mobile phase (acetonitrile) used in HILIC is especially compatible with ESI-MS, resulting in high sensitivity.
Scope of the present study is to prove that the assessment of breast cancer markers by LC/ESI-MS is feasible and diagnostically valuable. This technique shows a resolution advantage for assaying choline derivatives, and potentially many other target molecules, compared to NMR, and could complement the latter.
After the necessary large scale standardization of protocols, mass spectrometry (MS) could reduce the traumatic impact of current bioptic procedures based on its sensitivity and, eventually, replace the current diagnostic protocols. 
Experimental section

Reagents
Standard compounds were obtained from SigmaAldrich. Choline, phosphocholine and glycerophosphocholine were respectively in the form of choline chloride, phosphorylcholine chloride calcium salt tetrahydrate and sn-glycero-3-phosphorylcholine 1:1 cadmium chloride adduct. All solvents used were of HPLC grade.
Instrumentation
The LC/MS system consisted of a QqTOF mass spectrometer (Q-STAR by Applied Biosystems-SCIEX) equipped by an electrospray ionization (ESI) source and an Agilent 1100 series micro LC pump. 1 H NMR experiments were acquired on a Bruker Avance spectrometer operating at 500 MHz.
Tissue extraction
Human breast-tissue specimens were obtained from three patients (referred to as patients A, B, C) by surgical excision (Table 1 ). In any case a double resection was performed, the first from the active proliferating carcinoma and the second from healthy tissue by sampling 2 cm away from the tumor margin. The samples were immediately frozen in liquid nitrogen after collection and then stored at -80 • C until the time of metabolites extraction and analysis.
Choline compounds were extracted from tissue by a method derived from Bligh and Dyer [3, 6] . The frozen samples were pulverized by an ULTRA-TURRAX T25 Homogenizer (IKA). To prevent thawing the biopsies were put in plastic test tube and kept dipped into liquid nitrogen during the whole smashing process. The frozen tissue from mammary specimens was weighted after pulverization and ranged roughly between 100 and 300 mg. Immediately after weighting, the following extraction protocol was performed (solvents volumes are related to 100 mg of pulverized tissue):
1) The frozen powder was suspended in 0.400 ml methanol/chloroform (2:1 v/v) and, after thorough vortexing, left overnight at -20 • C. 2) The sample was then centrifuged at 1500 g for 5 minutes and the supernatant extract was separated and stored at -20 • C. 3) The residue was submitted to re-extraction with 0.250 ml of methanol/chloroform/water (2:1:0.8 by volume) and left at -20 • C for at least four hours. 4) The supernatants from both extractions were combined and, after addition of first 0.100 ml of chloroform and then 0.100 ml of water, the resulting solution was submitted to 5 minutes centrifugation. The procedure separates two phases: an aqueous phase containing methanol at the top and an organic phase at the bottom; in some case denatured proteins was observed in the middle. 5) The aqueous phase (that contains the hydrosoluble choline compounds) was directly lyophylized and then redissolved in 0.020 ml water and 0.800 ml methanol (2.4% H 2 O by volume). The resulting minute amounts of precipitates (proteins) were removed by filtration with 0.2m filters. The filtrated solution was stored at -80 • C until it was used for either LC/ESI-MS or NMR analysis.
LC/ESI-MS
Analysis
The LC-MS method previously reported [7] was adopted with minor modifications. Aqueous extracts from mammary tissue samples were dried and rediluted in a mixture of of acetonitrile/water/methanol = 7/1/2 and then submitted to LC separation and MS analysis (injected volume 5 l, corresponding to the content of 1 mg of pulverized tissue). Chromatographic separation of choline compounds, namely choline (Cho), phosphorylcholine (PCho) and glycerophosphorylcholine (GPCho) was obtained with a HILIC TSK-Gel Amide-80 column 5m (length 150 mm and ID 0.50 mm from GRACE). The eluent composition was: H 2 O 99.9%, 0.1% HCOOH and 5 mM [(NH 4 ) + (CH 3 COO) − ] for mixture A; 97.9% CH 3 CN, 2.0% H 2 O and 0.1% HCOOH for mixture B. The following 60-minute gradient program was used: from 0th to 5th minute column conditioning at 80% of B; from 5th to 40th minute, B gradient from 80% to 10%; from 40th to 45th minute, B percentage fixed at 80%; finally from 45th to 60th minute back-gradient from 10% to 80% of mixture B. The flow rate was set at 10 L/min.
Positive ESI parameters for standard MS scan were tuned for best sensitivity under HPLC conditions. Nitrogen was used as nebulizer gas (GS1) and curtain gas (CUR): GS1 and CUR were set respectively at 20.00 and 15.00 psi. The DP (declustering potential), FP (focusing potential) and DP2 (secondary declustering potential) were set respectively at 40, 230 and 15 V. The ion spray voltage (IS) was 5 kV. The positively charged molecular ions of choline compounds were monitored by extracting the ion chromatogram of selected mass ranges including the target molecules mass.
Data treatment
The analytes peaks were integrated with the software Analyst QS 1.1 (Applied Biosystems-SCIEX) by evaluating the extracted ion content (XIC) counts. The correspondence between measured XIC counts and absolute concentrations was established by calibration curves with standard compounds.
Details can be found in the Supplementary Material Section.
NMR spectroscopy 2.5.1. Analysis
An aliquot of each aqueous extract (corresponding to 75 mg of frozen pulverized tissue) was dried under vacuum and redissolved in 0. Monodimensional 1 H spectra were collected using a sweep width of 8 kHz and a time domain of 8 K complex data points, with 64 acquisitions and 8 silent scans. Flip-angle pulses of 30 • were applied with a relaxation delay of 5 s. Presaturation was used for suppression of the HOD signal during the whole initial delay. The adopted pulse sequence includes the Electronic Reference Signal (ERETIC TM ) [2] synthesized by an electronic device, which was used for the determination of absolute concentrations. The reference signal provides a pseudo-FID that has all the characteristics of a real NMR signal, after proper calibration, and whose parameters (frequency, magnitude, phase, T2) are controlled from the spectrometer console. Spectra acquisition and processing were performed with the Bruker software TOPSPIN.
Data treatment
After FID apodization with a shifted sine square window function (90 • ) all spectra were phased, Fourier-transformed and chemical-shift referenced. The integral value of significant peaks were measured. In some cases Gaussian window multiplication of the FID was necessary to enhance resolution of signals: the deconvolution of the envelopes of interest was performed by fitting a mixed Lorentzian/Gaussian lineshape to the experimental pattern. The peak modeling, performed with TOPSPIN, was used only for the estimate of the integral fractions to be assigned to the single components of peak envelopes.
The absolute quantification of metabolites of interest (namely Cho, PCho, GPCho) was based on N-trimethyl peaks (Fig. 2) , which are the most intense and isolated in mono-dimensional spectra, relative to the ERETIC signal. The artificial peak was used as an internal standard whose equivalent concentration [ERETIC] was calibrated against the absolute concentrations of three standard compounds. Further details can be found in the Supplementary Material Section.
Results
Extraction protocol
The very first step of frozen tissue pulverization was modified with respect to our previously reported protocol [7] . This is crucial for samples as inhomogeneous as typical mammary biopsies. In particular instead of grinding the frozen sample with a scalpel, we used a homogenizer (model ULTRA-TURRAX T25, by IKA) provided with a stainless steel disperser tool. The small diameter of the steel tip (8 mm) allowed working on biopsies which were located in plastic test tube and kept dipped into liquid nitrogen during the whole smashing process. This method resulted in an efficient grinding of tissue: the whole operation could be accomplished in 5-10 minutes depending on the sample. Furthermore keeping biopsies dipped into liquid nitrogen avoids sample thawing, a bad eventuality for chemical stability of labile metabolite and for their reliable quantification.
LC/ESI-MS
The LC/ESI-MS analysis of the bioptic aqueous extracts focused on three significant metabolites for cancer diagnosis: Cho, PCho, and GPCho. The three molecules are hydrosoluble and positively charged, due to the choline moiety, hence all are detected by ESI-MS under positive mode.
The protocol for chromatographic separation and mass spectrum acquisition had been already established [7] , therefore only small modifications were made, to improve the chromatographic separation (see Experimental Section).
The Total Ion Current (TIC) Chromatogram of a standard mixture solution of Cho, PCho, GPCho is shown in Fig. 3 ; the HILIC separation efficiency for the Cho compounds can be appreciated by looking at the extracted ion chromatograms (XICs) obtained by selecting the specific m/z values and thus discarding the baseline and co-eluting ions. The quantification of Cho compounds in the biological samples was based on their XICs: representative samples chromatograms are shown in Fig. 4 .
The concentration of free Cho and Cho derivatives obtained by LC/ESI-MS analysis are reported in Table 2 .
NMR
Bioptic aqueous extracts, obtained as described in Experimental Section, were analyzed by 1 H 1D NMR without any buffer addition. Examples of full spectra relative to two representative biologic samples are shown in Fig. 5 ; the enlarged choline region of the same spectra is reported in Fig. 6 and compared to a mixture of standard Cho, PCho and GPCho in D 2 O. The quantification of Cho, PCho and GPCho exploited the resonances of the respective N-trimethyl groups that originate very intense singlets. The specific peaks were identified in the region between 3,15 and 3,35 ppm where, besides choline and derivatives, a number of other signals occur (phosphoethanolamine, taurine, betaine, etc.). The chemical shifts of the Ntrimethyl groups vary depending on the sample pH; in neutral solutions the chemical shifts are: 3,20 ppm for Cho, 3,22 ppm for PCho and 3,23 ppm for GPCho. The assignment was based on a report by Sitter et al. [9] and was confirmed by comparison with the spectra of synthetic standard mixtures recorded at different pH conditions (data not reported).
The Cho compounds estimation resulting by 1D NMR analysis is reported in Table 3 .
Discussion
Sample choice
The first qualifying point of the present study is the availability of a double specimen for each of the three enrolled patients: the first derived from the proliferating carcinoma and the second from healthy tissue outside the tumor margin. Though in principle every metabonomic study should consider cancer biopsies and healthy tissue controls from the same individuals, i.e. internal controls, to account for the individual metabolome variability, this is not always possible and many theoretical conclusions on metabolic markers are based on the differential absolute concentrations in cancerous and normal tissues, without taking into account the tissue source. In this study, on the contrary, we could exclude that the concentration changes of choline compounds were related to the intrinsic variability among individuals.
Methodology: NMR vs LC-MS
NMR and Mass Spectrometry (MS) represent the principal approaches in metabolomics/metabonomics studies. In this type of application, NMR has many advantages such as high information content of the resulting spectra, ease of quantification and little need of optimization for the analysis conditions. MS techniques can cover a wide chemical diversity with high sensitivity and resolution, but require a preliminary optimization of the chromatographic separation.
The present study highlights the complementarity of the two analytical approaches. We adopted 1D NMR as conventional reference technique to collect a full set of information on the aqueous extract of biopsies. The use of 1D NMR for the analysis of unfractionated tissue extract, with hundreds of overlapping resonances can not afford complete assignment and accurate peak integration. For the quantitative determination of our target biomarkers with well established assignment, however, we could adopt the approach of fitting overlapped 1D spectra with modeled peaks. The modeling approach allowed the concentration estimate of Cho, PCho and GPCho in the whole set of sample, though for 2 out of 6 samples it was not possible to resolve PCho and GPCho, and only the total amount of the two compounds was reported.
Differently, the combination of on-line HILIC separation and ESI-MS allowed to resolve the target peaks without the necessity of chemical derivatization. The LC-MS quantification of Cho derivatives in the test samples was obtained by interpolation of the LC-MS response, based on calibration curves obtained under the same experimental conditions. Although LC-MS quantitative assessment is safely carried out based on isotopically labeled internal standards, the response for Cho compounds is reasonably linear over the working range (correlation coefficients between 0.9686 and 0.9892 low R 2 values due to random errors). Some critical aspects of the LC-MS approach, that arise from reproducibility of the measurements, remain inherently unavoidable. Some significant metabolite level differences observed in Tables 2 and 3 could be due to the inherent reproducibility differences of the LC-MS and NMR techniques, as well as to plausible differences in hydrolysis pattern of the Cho metabolite pools in the samples submitted to either LC-MS or NMR analysis. Further analysis of sample groups of significant size will more properly address this issue. Table 2 Results of LC-MS estimate of Cho and its phosphorylated derivatives concentrations. The confidence limits were derived from equation (1) Table 3 Results of 1D NMR estimate of Cho and its phosphorylated derivatives concentrations. The errors were derived from equation (4) 
Breast cancer diagnosis: Implications of choline-containing biomarkers
As reviewed by Podo [8] in 1999 and by Glunde et al. in 2006 [4] , elevated PCho content represents a general feature of most tumours and is related to the enhancement of the so-called 1 H "choline peak" (tCho) centered at 3.2 ppm and observed in MR spectra of cancerous tissue in vivo. [the tCho peak may actually comprise signals from choline-containing compounds, such as GPCho and PCho, as well as free Cho itself, together with contributions from other metabolites, such as phosphoethanolamine, inositol and taurine]. It should be considered that PCho alteration is not exclusive to malignancy, since it may also occur in other cases of accelerated tissue proliferation like for instance benign tumours or developing (embryo or fetal) organs.
According to Glunde, in breast cancers, a switch from high GPCho and low PCho to low GPCho and high PCho is precisely correlated with malignant transformation of cells. In addition several lines of evidence confirm the significance of the PCho/GPCho ratio as a possible indicator of altered phospholipid turnover during tumour progression; while elevated concentrations of PCho may simply reflect high rate of cell proliferation (for either tumour or normal cells). Consequently, the role of specific indicator of malignancy might be attributed to the PCho/GPCho ratio. These concepts were the starting point of the present study which aimed at establishing robust analytical methods for measuring choline related cancer biomarkers such as PCho level, PCho/GPCho ratio, and tCho level in tissue samples. Indeed our results demonstrate that even significant metabolite level differences estimated by different techniques are compensated when analysed within the interpretation frame above defined (Figs. 7 and 8 ). Therefore we consider our results a proof of concept and propose the collection of a statistically representative data pool, to improve the definition of quantitative standards. Based on the current LC-MS and NMR analysis, the PCho tumour /PCho control ratio varies between 6 and 13, while the indicator PCho/GPCho increases by some 3 to 7-fold in cancer lesion compared to healthy tissue.
Concluding remarks
The extraction and analytical methods described in this study offer useful tools to determine absolute metabolite concentrations in tissue extracts, and more generally in complex biological mixtures. An optimized implementation of a LC/ESI-MS method for the absolute determination of Cho and its phosphorylated derivatives is compared with a 1D-1 H NMR spectroscopy method entailing an internally-synthesized radiofrequency reference such as ERETIC TM .
Besides possible sample alterations, we encountered limited reproducibility problems in LC/ESI-MS quantifications related to external calibrations that can be avoided using an internal isotopically-labelled reference standard.
In addition the complexity of tissue extracts metabolomics is well known, especially when compared to biofluids or cell lines studies, because of the heterogeneity of tissues resections undergoing pulverization and extraction and the high dynamic range among metabolite concentrations.
In spite of these drawbacks, a reasonable agreement between LC/ESI-MS and NMR analysis was found and an efficient discrimination between control and cancerous tissue was possible. While the three different biopsies, with the relative healthy tissue counterparts, here analyzed represent a proof of concept of significance and robustness of tCho and PCho levels and PCho/GPCho ratio, the whole protocol will need to be extended to a significant number of samples in order to validate statistically a sound quantitative refinement of its potentialities.
Once a proper statistical size will be available, the data set collected by NMR and LC/ESI-MS could be analyzed from the perspective of untargeted metabolomics as well. In fact it should be possible to apply multivariate statistics in order to verify the possibility of new correlation between metabolic alterations and malignant proliferation.
With respect to more conventional diagnostic tools, such as histology or immunohistochemistry, NMR and MS provide a large amount of information that enable database processing to extract unique correlation. To calibrate the ERETIC peak we acquired the 1 H spectrum of a reference mixtures of standard Cho, PCho and GPCho, each one 1 mM in 0.5 ml of D 2 O. We adopted as equivalent concentration for the artificial peak, the average of the values derived from the three reference compounds. The precision of the obtained average value for [ERETIC], namely 0.028 mM, was good as shown by the relative standard deviation, namely 0.00048.
The analytes quantification was certainly affected by the low intensity of the target peaks compared to noise; the error level in metabolite concentrations was derived by error propagation rules, from the error (S A ) associated to each integral area value (A Comp ). The S A value was calculated from the spectrum signal to noise ratio (SNR) according to the following formula:
The SNR value was determined for each 1D spectrum by the software TOPSPIN according to the definition: (5) where maxval is the highest intensity in the signal region and noise factor is referred to a fixed region where no signals are detected.
